on Emerald Clinical Trials
Emerald Clinical Trials Welcomes Michael Stibilj as New CEO
Emerald Clinical Trials, a prominent clinical research organization based in Asia-Pacific, announces Michael Stibilj's appointment as Chief Executive Officer on October 1, 2026. Stibilj, with over 30 years in the global CRO industry, will lead the company into its next growth phase.
Stibilj brings a wealth of experience, having previously served as COO at Novotech and CEO at PPC Group. His expertise spans transformational leadership and significant revenue growth, especially within the Asia-Pacific region.
This leadership change comes after Emerald Clinical's acquisition of Hongyi Clinical Development Services, expanding its capabilities to over 1,000 professionals globally. The company is positioned as a leading platform in clinical development, spanning 40+ countries.
The board expresses confidence in Stibilj's ability to guide Emerald Clinical's future, leveraging his global insight and Asia-Pacific depth to enhance the company's market position.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Emerald Clinical Trials news